MASH is a leading cause of liver transplantation
Maria Guadalupe Cardenas, MD, provides medical leadershipeligibility, dosing, monitoring, and multi-morbidity management
In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)
When choosing collagen supplements, select products from reputable manufacturers that undergo rigorous quality testing
Health Plan Coverage There is no broad federal mandate requiring employer-sponsored health plans to cover GLP-1 drugs for the treatment of diabetes or obesity
Is this safe long-term? Can I combine this with my blood pressure meds? What if I miss a dose? Nothing is off-limits